Search

• ViiV Healthcare presents phase III data

  Media

  An investigational two drug-regimen of maraviroc with DRV/r showed inferior efficacy compared to emtricitabine/tenofovir with DRV/r.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-phase-iii-data/

  First published: 22 July 2014

• ViiV Healthcare announces detailed positive phase III results for investigational two-drug regimen of dolutegravir and rilpivirine for HIV treatment

  Media

  Headline results were announced in December 2016 and detailed study results are being presented at the annual Conference

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-detailed-positive-phase-iii-results-for-investigational-two-drug-regimen-of-dolutegravir-and-rilpivirine-for-hiv-treatment/

  First published: 13 February 2017

• ViiV Healthcare presents three-year data for investigational long-acting injectable, two-drug HIV regimen

  Media

  LATTE-2 study shows high rates of virologic response & long-term durability with long-acting, injectable, two-drug regimen over 160 weeks.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-three-year-data-for-investigational-long-acting-injectable-two-drug-hiv-regimen/

  First published: 29 October 2018

• ViiV Healthcare submits regulatory application to European Medicines Agency for investigational cabotegravir to be used in combination with rilpivirine as the first monthly, injectable treatment for HIV

  Media

  The marketing application is based on phase III ATLAS and FLAIR trials in which the regimen showed similar efficacy to daily, 3-drug one.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-regulatory-application-to-european-medicines-agency-for-investigational-cabotegravir-to-be-used-in-combination-with-rilpivirine/

  First published: 29 July 2019

• EACS 2019: ViiV Healthcare to present 17 abstracts from its portfolio addressing the diverse needs of people living with HIV

  Media

  Data presentations expand understanding of ViiV Healthcare’s pipeline for heavily treatment-experienced populations.

  https://www.gsk.com/en-gb/media/press-releases/eacs-2019-viiv-healthcare-to-present-17-abstracts-from-its-portfolio-addressing-the-diverse-needs-of-people-living-with-hiv/

  First published: 06 November 2019

• ViiV Healthcare files submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV

  Media

  If approved, DTG will be the first integrase inhibitor available as a dispersible tablet for children living with HIV.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-files-submissions-to-the-fda-and-ema-for-the-first-ever-dispersible-formulation-of-dolutegravir-dtg-for-children-living-with-hiv/

  First published: 13 December 2019

• ViiV Healthcare presents long-term switch data for Dovato demonstrating non-inferior efficacy in adults with HIV-1 and zero cases of virologic failure versus continuation of a 3-drug TAF-based regimen

  Media

  The TANGO 96-week data presented at HIV Glasgow 2020 also confirm Dovato’s well-established safety and tolerability profile

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-long-term-switch-data-for-dovato/

  First published: 08 October 2020

• ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside pipeline advances at CROI 2021

  Media

  16 sponsored abstracts from our diverse portfolio of innovative pipeline and licensed HIV treatment and prevention options will be presented

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-new-data-on-long-acting-regimens-for-hiv-prevention-and-treatment-alongside-pipeline-advances-at-croi-2021/

  First published: 02 March 2021

• ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs

  Media

  The Phase 3 TANGO study is the 3rd trial to provide long-term evidence for Dovato reinforcing its use as a viable switch for people with HIV

  https://www.gsk.com/en-gb/media/press-releases/viiv-presents-three-year-switch-data-for-dovato/

  First published: 29 September 2021

• ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV

  Media

  ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study

  https://www.gsk.com/en-gb/media/press-releases/aria-study-shows-superior-efficacy-of-triumeq-for-treatment-naïve-women-living-with-hiv/

  First published: 18 July 2016